/BNTC
BNTC Stock - Benitec Biopharma Inc.
Healthcare|BiotechnologyNASDAQ
$11.50+1.05%
+$0.12 (+1.05%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.15
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+158.0%upside
Target: $29.67
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BNTC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.38 – $11.62
TARGET (TP)$29.67
STOP LOSS$10.58
RISK/REWARD1:19.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.20
52W High$17.15
52W Low$9.70
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $75,000 | $73,000 | $59,000 |
| Gross Profit | $-396,000 | $-343,000 | $-306,000 | $64,000 | $-64,000 |
| Gross Margin | N/A | N/A | -408.0% | 87.7% | -108.5% |
| Operating Income | $-41,765,000 | $-22,598,000 | $-19,081,000 | $-17,854,000 | $-13,596,000 |
| Net Income | $-37,917,000 | $-21,751,000 | $-19,562,000 | $-18,208,000 | $-13,882,000 |
| Net Margin | N/A | N/A | -26082.7% | -24942.5% | -23528.8% |
| EPS | $-1.05 | $-2.68 | $-14.12 | $-19.31 | $-27.27 |
Company Overview
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish0 Neutral/Bearish
Price Targets
$26
Average Target
↑ 121.7% Upside
Now
$13
Low
$26
Average
$35
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 7th 2025 | TD Cowen | Initiation | Buy | - |
| December 16th 2024 | H.C. Wainwright | Initiation | Buy | $28 |
| December 13th 2024 | Robert W. Baird | Initiation | Outperform | $30 |
| October 16th 2024 | Oppenheimer | Initiation | Outperform | $35 |
| September 12th 2024 | Guggenheim | Initiation | Buy | $17 |
| July 22nd 2024 | Leerink Partners | Initiation | Outperform | $13 |
| June 13th 2024 | Piper Sandler | Initiation | Overweight | $30 |
Earnings History & Surprises
BNTCBeat Rate
40%
Last 15 quarters
Avg Surprise
-389.0%
EPS vs Estimate
Beats / Misses
6/9
Last 12 quarters
Latest EPS
$-0.22
Q4 2025
EPS Surprise History
Q1 24
-576.9%
$-2.64vs$-0.39
Q2 24
-110.3%
$-1.64vs$-0.78
Q3 24
-169.4%
$-1.32vs$-0.49
Q4 24
+21.3%
$-0.48vs$-0.61
Q1 25
+64.0%
$-0.36vs$-1.00
Q2 25
+33.3%
$-0.24vs$-0.36
Q3 25
-50.0%
$-0.42vs$-0.28
Q4 25
+37.1%
$-0.22vs$-0.35
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Feb 13, 2026 | $-0.23 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.35 | $-0.22 | +37.1% | ✓ BEAT |
Q3 2025 | Sep 22, 2025 | $-0.28 | $-0.42 | -50.0% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.36 | $-0.24 | +33.3% | ✓ BEAT |
Q1 2025 | Feb 14, 2025 | $-1.00 | $-0.36 | +64.0% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-0.61 | $-0.48 | +21.3% | ✓ BEAT |
Q3 2024 | Sep 26, 2024 | $-0.49 | $-1.32 | -169.4% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.78 | $-1.64 | -110.3% | ✗ MISS |
Q1 2024 | Feb 13, 2024 | $-0.39 | $-2.64 | -576.9% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-0.51 | $-2.76 | -441.2% | ✗ MISS |
Q3 2023 | Sep 21, 2023 | $-3.23 | $-2.83 | +12.4% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.20 | $-2.72 | -1260.0% | ✗ MISS |
Q1 2023 | Feb 13, 2023 | $-0.11 | $-3.40 | -2990.9% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-2.04 | $-7.99 | -291.7% | ✗ MISS |
Q3 2022 | Sep 2, 2022 | $-4.76 | $-10.54 | -121.4% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-7.48 | $-6.80 | +9.1% | ✓ BEAT |
Q1 2022 | Feb 14, 2022 | — | $-10.03 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-10.54 | — | — |
Q3 2021 | Sep 20, 2021 | — | $-5.10 | — | — |
Latest News
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Lowers Price Target to $32
➖ NeutralBenzinga•Nov 24, 2025, 01:06 PM
Benitec Biopharma Q1 EPS $(0.22) Beats $(0.41) Estimate
📈 PositiveBenzinga•Nov 14, 2025, 10:01 PM
Benitec Biopharma shares are trading lower after the company announced the pricing of its $100 million offering.
📉 NegativeBenzinga•Nov 6, 2025, 02:02 PM
Benitec Biopharma Prices $100M Offering Including 5.93M Common Shares And Concurrent 1.48M Share Direct Offering At $13.50 Each
➖ NeutralBenzinga•Nov 6, 2025, 07:35 AM
Benitec Biopharma Announces Underwritten Common Stock Offering; Terms Not Disclosed
📉 NegativeBenzinga•Nov 5, 2025, 09:44 PM
HC Wainwright & Co. Maintains Buy on Benitec Biopharma, Raises Price Target to $35
📈 PositiveBenzinga•Nov 4, 2025, 05:30 PM
Citizens Maintains Market Outperform on Benitec Biopharma, Raises Price Target to $22
📈 PositiveBenzinga•Nov 4, 2025, 12:34 PM
Benitec Biopharma shares are trading lower. The company announced interim clinical results for the BB-301 Phase 1b/2a Clinical Trial.
📉 NegativeBenzinga•Nov 3, 2025, 01:53 PM
Benitec Biopharma Plans To Meet With FDA In 2026 To Confirm BB-301 Pivotal Study Design
➖ NeutralBenzinga•Nov 3, 2025, 12:14 PM
Benitec Biopharma Provides Interim Clinical Results For BB-301 Phase 1b/2a Clinical Trial. Following Administration Of BB-301, Cohort 1 Patients Showed Significant, Sustained Improvements Across Multiple Clinical Measures
📈 PositiveBenzinga•Nov 3, 2025, 12:13 PM
Reported Sunday, Benitec Biopharma Announces Upcoming Phase 1b/2a BB-301 Clinical Study Update For Oculopharyngeal Muscular Dystrophy Patients In November 3, 2025 Webcast
📈 PositiveBenzinga•Nov 3, 2025, 07:45 AM
JMP Securities Reiterates Market Outperform on Benitec Biopharma, Maintains $20 Price Target
📈 PositiveBenzinga•Sep 24, 2025, 01:02 PM
Benitec Biopharma Files For Mixed Shelf Offering Of Up To $200M
➖ NeutralBenzinga•Sep 22, 2025, 09:27 PM
CORRECTION: Benitec Biopharma Q4 EPS $(0.42) Misses $(0.33) Estimate
📉 NegativeBenzinga•Sep 22, 2025, 09:12 PM
Benitec Biopharma Q4 EPS $0.00 Beats $(0.33) Estimate
📈 PositiveBenzinga•Sep 22, 2025, 08:08 PM
Oppenheimer Maintains Outperform on Benitec Biopharma, Lowers Price Target to $29
➖ NeutralBenzinga•Sep 16, 2025, 03:56 PM
Frequently Asked Questions about BNTC
What is BNTC's current stock price?
Benitec Biopharma Inc. (BNTC) is currently trading at $11.50 per share. The stock has moved +1.05% today.
What is the analyst price target for BNTC?
The average analyst price target for BNTC is $29.67, based on 1 analyst.
What sector is Benitec Biopharma Inc. in?
Benitec Biopharma Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BNTC's market cap?
Benitec Biopharma Inc. has a market capitalization of $0.30 billion, making it a small-cap company.
Does BNTC pay dividends?
No, Benitec Biopharma Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAUTL
Autolus Therapeutics plc
$1.63
Mkt Cap: $0.4B
GALT
Galectin Therapeutics Inc.
$4.38
Mkt Cap: $0.3B
IMAB
I-Mab
$3.95
Mkt Cap: $0.3B
LCTX
Lineage Cell Therapeutics, Inc.
$1.68
Mkt Cap: $0.4B
NGNE
Neurogene Inc.
$20.55
Mkt Cap: $0.3B
OCGN
Ocugen, Inc.
$1.40
Mkt Cap: $0.4B
PRTC
PureTech Health plc
$16.78
Mkt Cap: $0.4B
QSI
Quantum-Si incorporated
$1.27
Mkt Cap: $0.2B
SLDB
Solid Biosciences Inc.
$5.94
Mkt Cap: $0.5B
XOMA
XOMA Royalty Corp.
$25.39
Mkt Cap: $0.3B
Explore stocks similar to BNTC for comparison